Catherine Roche
Overview
Explore the profile of Catherine Roche including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
199
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Mohamed A, Romano D, Saveanu A, Roche C, Albertelli M, Barbieri F, et al.
Oncotarget
. 2017 Apr;
8(25):41044-41063.
PMID: 28454119
Therapeutic management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is challenging. The mammalian target of rapamycin (mTOR) inhibitor everolimus recently obtained approval from the Food and Drug Administration for the treatment of...
12.
Cuny T, Zeiller C, Bidlingmaier M, Defilles C, Roche C, Blanchard M, et al.
Endocr Relat Cancer
. 2016 Jun;
23(7):509-19.
PMID: 27267119
Pegvisomant (PEG), an antagonist of growth hormone (GH)-receptor (GHR), normalizes insulin-like growth factor 1 (IGF1) oversecretion in most acromegalic patients unresponsive to somatostatin analogs (SSAs) and/or uncontrolled by transsphenoidal surgery....
13.
Jullien N, Roche C, Brue T, Figarella-Branger D, Graillon T, Barlier A, et al.
PLoS One
. 2015 Mar;
10(3):e0120010.
PMID: 25822178
To test the role of wtPIT-1 (PITWT) or PIT-1 (R271W) (PIT271) in somatolactotroph cells, we established, using inducible lentiviral vectors, sublines of GH4C1 somatotroph cells that allow the blockade of...
14.
Chalabi-Dchar M, Cassant-Sourdy S, Duluc C, Fanjul M, Lulka H, Samain R, et al.
Gastroenterology
. 2015 Feb;
148(7):1452-65.
PMID: 25683115
Background & Aims: The KRAS gene is mutated in most pancreatic ductal adenocarcinomas (PDAC). Expression of this KRAS oncoprotein in mice is sufficient to initiate carcinogenesis but not progression to...
15.
Cuny T, Mohamed A, Graillon T, Roche C, Defilles C, Germanetti A, et al.
Mol Cell Endocrinol
. 2012 Feb;
355(1):106-13.
PMID: 22348806
Objective: As prolactinomas fail to respond to dopamine agonist (DA) in 10-20% of cases, we hypothesized that somatostatin subtype 2 receptor (sst2) overexpression in DA-resistant prolactinomas may enhance suppression of...
16.
Roche C, Rasolonjanahary R, Thirion S, Goddard I, Fusco A, Figarella-Branger D, et al.
Hum Gene Ther
. 2011 Sep;
23(1):104-14.
PMID: 21942649
The treatment of growth hormone (GH)- and prolactin (PRL)-secreting tumors resistant to current therapeutic molecules (somatostatin and dopamine analogues) remains challenging. To target these tumors specifically, we chose to inactivate...
17.
Acunzo J, Roche C, Defilles C, Thirion S, Quentien M, Figarella-Branger D, et al.
Endocrinology
. 2011 Aug;
152(10):3884-92.
PMID: 21810944
Nonfunctioning pituitary adenomas (NFPA; gonadotroph derived), even not inducing hormonal hypersecretion, cause significant morbidity by compression neighboring structures. No effective and specific medical methods are available so far for treating...
18.
Abdelhakim A, Barlier A, Kebbou M, Benabdeljalil N, Timinouni M, Taoufiq F, et al.
J Cancer Res Ther
. 2009 Oct;
5(3):198-202.
PMID: 19841562
Background: Germline RET gene mutations are well known to be the genetic causes of multiple endocrine neoplasia type 2 (MEN2) and may be identified by genetic screening. Aim: The purpose...
19.
Acunzo J, Thirion S, Roche C, Saveanu A, Gunz G, Germanetti A, et al.
Cancer Res
. 2008 Dec;
68(24):10163-70.
PMID: 19074883
In human somatotroph adenomas, growth hormone (GH) hypersecretion can be inhibited by somatostatin analogues such as octreotide. Unfortunately, serum GH levels reach normal values in only 60% of treated patients....
20.
Ayzac L, Beruard M, Girard R, Hannoun J, Kuentz F, Marc J, et al.
Nephrol Ther
. 2008 Sep;
5(1):41-51.
PMID: 18815088
Aim And Background: To show results of the first year of an infection surveillance network for haemodialysis patients (Dialin). In order to improve the security and quality of care, six...